Scribe Therapeutics files for a Nasdaq IPO under ticker SCTX, testing investor appetite for early-stage biotechs still short of Phase 3 data.
Benjamin Oakes, CEO Scribe Therapeutics
July 2, 2026 06:20 PM EDT
DealsIPOs
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Kyle LaHucik
Scribe Therapeutics raised $128.7M in its upsized IPO and surged 67% on its Nasdaq debut, signaling renewed biotech investor…
Scribe Therapeutics prices its Nasdaq IPO (SCTX), kicking off a wave of six biotechs expected to go public in the coming weeks.
The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other…
Scribe markets its Nasdaq IPO at a $14 midpoint for ~$96M net proceeds; Scholar Rock's apitegromab awaits an FDA call on Novo…
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go…
